Equities analysts expect that Merus NV (NASDAQ:MRUS) will post earnings of ($0.90) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Merus’ earnings, with the lowest EPS estimate coming in at ($0.91) and the highest estimate coming in at ($0.88). Merus reported earnings of ($0.95) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 5.3%. The firm is expected to report its next earnings results on Thursday, November 29th.
On average, analysts expect that Merus will report full year earnings of ($2.60) per share for the current fiscal year. For the next financial year, analysts expect that the company will post earnings of ($4.01) per share, with EPS estimates ranging from ($4.57) to ($3.44). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that follow Merus.
MRUS has been the topic of a number of research analyst reports. Wedbush reiterated an “outperform” rating and issued a $34.00 target price (up from $26.00) on shares of Merus in a research note on Friday, July 27th. BidaskClub lowered shares of Merus from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 24th. Zacks Investment Research lowered shares of Merus from a “buy” rating to a “hold” rating in a research note on Friday. Finally, ValuEngine lowered shares of Merus from a “buy” rating to a “hold” rating in a research note on Monday, September 24th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $28.00.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Aquilo Capital Management LLC acquired a new stake in Merus during the second quarter worth about $28,470,000. Stanley Laman Group Ltd. boosted its holdings in shares of Merus by 23.7% in the second quarter. Stanley Laman Group Ltd. now owns 57,396 shares of the biotechnology company’s stock valued at $1,306,000 after acquiring an additional 10,982 shares in the last quarter. DRW Securities LLC bought a new stake in Merus during the second quarter worth approximately $286,000. Renaissance Technologies LLC boosted its holdings in Merus by 26.8% during the second quarter. Renaissance Technologies LLC now owns 48,200 shares of the biotechnology company’s stock worth $1,097,000 after buying an additional 10,200 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in Merus during the first quarter worth approximately $267,000. Institutional investors own 54.43% of the company’s stock.
Merus Company Profile
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Recommended Story: How are institutional investors different from individual investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.